Lavanya Tiriveedhi, MD
Hematology & Oncology · Springfield, MONPI 1255539581
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 100 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $868, more than ten times the $24 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in MO, where the typical reported total is $1,571.
Across 100 payments — averaging $18.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$248
- E.r. Squibb & Sons, L.L.C.$224
- AstraZeneca$171
- Pfizer$145
- Array Biopharma Inc$122
- GSK$119
- plus $827 from 22 others
Across 1 payment — averaging $541.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$542
What the payments were for
- Food & beverage$1,74694%
- Education$1116%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 11 | $248 |
| E.r. Squibb & Sons, L.L.C. | 20 | $224 |
| AstraZeneca | 4 | $171 |
| Pfizer | 8 | $145 |
| Array Biopharma Inc | 8 | $122 |
| GSK | 5 | $119 |
| Eisai Inc. | 7 | $103 |
| Regeneron Healthcare Solutions, Inc. | 4 | $82 |
| Sanofi | 4 | $67 |
| Bristol Myers Squibb | 3 | $52 |
| Johnson & Johnson | 3 | $48 |
| Stemline Therapeutics Inc. | 2 | $44 |
| Merck | 2 | $42 |
| Tempus AI, Inc | 2 | $41 |
| Rigel Pharmaceuticals, Inc. | 2 | $40 |
| Acrotech Biopharma Inc. | 3 | $40 |
| Tersera Therapeutics LLC | 1 | $39 |
| Astellas Pharma US Inc | 1 | $32 |
| Beone Medicines USA, Inc. | 1 | $29 |
| Daiichi Sankyo Inc. | 1 | $26 |
| Incyte Corporation | 1 | $22 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| Gilead | 1 | $21 |
| Exelixis Inc. | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| AbbVie | 1 | $16 |
| Bayer | 1 | $14 |
| Servier Pharmaceuticals LLC | 1 | $12 |
How this compares
$1,857 in reported general payments places this provider in the 50th percentile of 211 hematology & oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 89 | $1,693,257 |
| IbrancePalbociclib | 55 | $854,562 |
| PomalystPomalidomide | 32 | $696,789 |
| CalquenceAcalabrutinib Maleate | 36 | $534,900 |
| ImbruvicaIbrutinib | 23 | $376,236 |
| Lenalidomide | 29 | $364,621 |
| XtandiEnzalutamide | 18 | $254,350 |
| LonsurfTrifluridine/Tipiracil Hcl | 18 | $233,721 |
| KisqaliRibociclib Succinate | 16 | $226,884 |
| Abiraterone Acetate | 76 | $185,267 |
| VenclextaVenetoclax | 14 | $179,915 |
| TasignaNilotinib Hcl | 11 | $108,461 |
| Everolimus | 22 | $75,914 |
| EliquisApixaban | 61 | $43,736 |
| XareltoRivaroxaban | 22 | $18,610 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $52 | $1,693,25789 claims |
| PfizerIbrance, Eliquis | $145 | $898,298116 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $224 | $696,78932 claims |
| AstraZenecaCalquence | $171 | $534,90036 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $17 | $376,23623 claims |
| NovartisKisqali, Tasigna | $248 | $335,34527 claims |
| Astellas Pharma US IncXtandi | $32 | $254,35018 claims |
| AbbVieVenclexta, Synthroid | $16 | $180,49027 claims |
| Johnson & JohnsonXarelto | $48 | $18,61022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 211 hematology & oncology providers in Missouri.
Other hematology & oncology in Springfield
- Raymond LobinsSpringfield$22K
- David SchlossmanColumbia$1.2M
- Mark FeslerSaint Louis$870K
- Kelly PendergrassLees Summit$189K
- Jonathan MizrahiSaint Louis$188K
- Shahzad RazaKansas City$123K
- Stephanie GraffKansas City$105K
- Muhammad MirzaWashington$65K
- Yifan TuSt. Louis$64K
- Whitney HensingKansas City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.